Clinical trial · Interventional
Yoga for Aromatase Inhibitor-associated Joint Pain
Evaluating Yoga for Aromatase Inhibitor-associated Joint Pain in Women With Breast Cancer: A Pilot Study
NCT01951976CI-TRIAL-00022832completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether it might be practical and useful to investigate the effectiveness of yoga classes in relieving joint pain associated with the use of a class of medications known as aromatase inhibitors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionnaires | Other | — | UNRESOLVED |
| Yoga Classes | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention Condition
- description
- Questionnaires and yoga classes. Group will attend a series of 90-minute yoga classes twice a week for 12 weeks.
- interventionNames
- Other: Questionnaires
- Other: Yoga Classes
Primary outcomes (2)
- measure
- Rate of Study Enrollment
- timeFrame
- 24 months
- description
- Acceptability of the proposed study to potential participants. The study will be considered acceptable if 50% or more of eligible participants agree to participate.
- measure
- Rate of Study Completion
- timeFrame
- Up to 24 weeks per participant
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have been diagnosed with stage 0-III breast cancer * Have completed local and/or adjuvant breast cancer therapy (with the exception of hormonal therapy) at least one month previously * Are post-menopausal defined as defined as no menses in the past 12 months * Are currently prescribed an aromatase inhibitor (AI) medication (anastrozole, letrozole, or exemestane) by a Moffitt-affiliated physician * Report joint pain that started or worsened after initiation of AI medication * Report worst pain score \> 4 in the preceding week on an 11-point (0-10) numeric rating scale Exclusion Criteria: * Have been diagnosed with another form of cancer (except nonmelanoma skin cancer) in the last five years * Have uncontrolled cardiac disease, pulmonary disease, or infectious disease * Have physical symptoms or conditions that could make yoga unsafe (i.e., neck injuries, dizziness, shortness of breath, chest pain, or severe nausea) * Have a body mass index (BMI) \> 40 kg/m\^2 (based on difficulties severly obese individuals may have with engaging in Iyengar yoga poses) * Have joint pain attributed to inflammatory arthritic conditions (i.e., rheumatoid arthritis, gout, pseudo-gout) per medical record or patient history * Had surgery within the past 3 months * Had injections of medication within the last 3 months to joint(s) currently painful * Are currently using corticosteroids or opioid medications * Are currently attending yoga classes * Do not speak or read standard English * Are scheduled or are planning to discontinue AI medication in the next 16 weeks * Do not have sufficient access to the Internet to complete study assessments
References
Publications (0)
Data not yet available
No reference posted for this study.